Clinical Trials Logo

Myotonic Dystrophy Type 1 clinical trials

View clinical trials related to Myotonic Dystrophy Type 1.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06075693 Recruiting - Clinical trials for Myotonic Dystrophy Type 1

Cerebrospinal Fluid Biomarkers of Myotonic Dystrophy

Start date: August 1, 2022
Phase:
Study type: Observational

Myotonic dystrophy is associated with central sleep apnea, excessive daytime sleepiness, diminished working memory, impaired visuospatial skills, and deficits in problem-solving skills. Cerebrospinal fluid (CSF) is a clear, colorless fluid that surrounds and protects the brain. Changes in the composition of CSF can serve as early indicators of changes in brain activity and function. The purpose of this research is to learn about myotonic dystrophy by examining cerebrospinal fluid and brain activity in participants. The tests will be low risk and are well tolerated. The information that we gather from this study may help us evaluate, prevent, diagnose, treat, and improve our understanding of myotonic dystrophy

NCT ID: NCT02269865 Recruiting - Clinical trials for Myotonic Dystrophy Type 1

Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy

CHRI
Start date: December 2013
Phase: N/A
Study type: Observational

Study to focus on the defining and managing the neuropsychological abnormalities of myotonic dystrophy and to find out if the neuropsychological abnormalities have any correlation with changes seen on Magnetic Resonance Imaging.

NCT ID: NCT00082108 Recruiting - Muscular Dystrophy Clinical Trials

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

Start date: September 2000
Phase:
Study type: Observational

Myotonic dystrophy (DM) and facioscapulohumeral muscular dystrophy (FSHD) are inherited disorders characterized by progressive muscle weakness and loss of muscle tissue. The purpose of this registry is to connect people with DM or FSHD with researchers studying these diseases. The registry will offer individuals with DM and FSHD an opportunity to participate in research that focuses of their diseases. The registry will also help scientists to accomplish research on DM and FSHD and to distribute their findings to patients and care providers.